Victoza pen 6mg/ml Novo Nordisk treats type 2 diabetes (1 pen)

Dosage form 1 box
Specifications Liraglutide
Ingredient Novo Nordisk

Ingredient

Composition information	Content
Liraglutide	6mg/ml

Uses

Indications

The drug is indicated by Victoza in the following cases:

Treatment of type 2 diabetes in adults to achieve blood sugar control. Metformin and Thiazolidinedione in patients who do not achieve adequate blood sugar control despite dual treatment.

pharmacokinetics

No information.

Before taking Victoza pen 6mg/ml Novo Nordisk treats type 2 diabetes (1 pen)

How to use

Inject subcutaneously.

Victoza is used once a day at any time, regardless of the meal, and can be injected under the skin into the abdomen, thighs or upper arms.

Victoza must not use intravenously or intramuscularly.

Dosage

Adults

The starting dose is 0.6mg of Liraglutide every day. After at least 1 week, the dose should be increased to 1.2mg, which can be increased by 1.8mg to improve blood glucose control. It is not recommended to use daily doses higher than 1.8mg.

Victoza can be added to therapy with metformin being used or coordinated therapy metformin and thiazolidinedione. The dose of metformin and thiazolidinedione are using can continue to be unchanged.

Victoza can be added with sulphonylurea therapy or Metformin and Sulphonylurea combination therapy. When adding victoza to therapy with sulphonylurea, it is necessary to consider reducing sulphonylurea dose to reduce the risk of blood glucose.

Special patient groups

Elderly (65 years old)

No need to adjust the dose based on age.

kidney failure

No dose adjustment for patients with mild renal impairment (Creatinine clearance 60 - 90ml/minute). Currently, Victoza is not recommended for patients with medium and severe renal failure including patients with end -stage renal disease.

Hepatic failure

Experience treatment in patients with liver failure is still very limited, so it is not recommended in patients with mild, medium or severe liver failure.

Group of children's patients

Safety and effectiveness of Victoza in children and teenagers under 18 have not been determined.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? The reported cases include serious nausea and vomiting. No reports include heavy hypoglycemia. All patients have recovered without complications.

In case of overdose, it is necessary to start appropriate support treatment according to the patient's clinical signs and symptoms.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Victoza, you may experience unwanted effects (ADR).

The most commonly reported side effects in clinical trials are digestive disorders: nausea and diarrhea are very common, while vomiting, constipation, abdominal pain and indigestion are common.

At the beginning of Victoza treatment, these digestive side effects may occur. These reactions usually decrease within a few days or weeks when continuing treatment. Headache and nasopharyngitis are also common.

Moreover, blood glucose is also common and is very common in the case of Liraglutide used in combination with a sulphonylurea. Most of the blood glucose has been mainly observed when combined with a sulphonylurea.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Victoza drugs are contraindicated in the following cases:

Hypersensitivity to the active ingredient or any component of the excipient.

Caution when using

should not use Victoz in patients with type 1 diabetes or to treat diabetes metonic acidosis. Victoza is not an alternative to insulin.

Pancreatitis

The use of GLP - 1 mutual substances is associated with the risk of pancreatitis. There have been several side reports on acute pancreatitis. If suspected acute pancreatitis, Victoza must be stopped and other potential suspected drugs.

thyroid disease

Side -thyroid reactions, including hypercondoemia, goiter and thyroid tumor have been reported in clinical trials, especially in patients with thyroid disease before and so Victoza should be used cautiously.

Dehydration

Signs and symptoms of dehydration, including renal failure and acute renal failure, have been reported in patients treated with Victoza.

Lower blood glucose

Patients who are taking Victoza in combination with a sulphonylurea may increase the risk of blood glucose. The risk of blood glucose may be reduced by reducing sulphonylurea dose.

The ability to drive and operate machinery

It is necessary to advise patients to be careful to avoid blood glucose while driving and operating machinery, especially when Victoza® is used in combination with a sulphonylurea.

Pregnancy

Pregnant women must not use Victoza® during pregnancy. If the patient wants to be pregnant or is pregnant, he/she must stop treatment with Victoza®.

Breastfeeding period

Due to lack of experience, do not use Victoza during breastfeeding.

Drug interaction

In the laboratory, Liraglutide shows that the ability to be very low in pharmacokinetic interaction with active ingredients related to cytochrome P450 and cohesion of plasma proteins.

Liraglutide slowing down can affect the absorption of oral drugs simultaneously, interactive studies do not show any clinical absorption slowly and thus do not require dose adjustment. Some patients treated with Victoza reported at least one severe diarrhea. Diarrhea can affect the absorption of oral drugs simultaneously.

paracetamol

Liraglutide does not change the overall absorption of paracetamol after taking a single dose of 1000mg. The highest concentration in plasma (CMAX) of Paracetamol decreased by 31% and the time to achieve the highest concentration in plasma (TMAX) on average up to 15 minutes slow. No need to adjust the dose when used simultaneously with paracetamol.

Atorvastatin

Liraglutide does not change the overall absorption of Atorvastatin to a clinical significance level after taking a single dose of Atorvastatin 40mg. Therefore, there is no need to adjust the dose of Atorvasta when used with Victoza, CMAX of Atorvastatin decreased by 38% and the average TMAX is slow from 1-3 hours when using Liraglutide.

griseofulvin

Liraglutide does not change the overall absorption of Griseofulvin after taking a single dose of Griseofulvin 500mg. Griseofulvin's CMAX increased by 37% while the average TMAX did not change. No need to adjust the dose of griseofulvin and other compounds with low solubility and high permeability.

digoxin

Use a single dose of Digoxin 1mg with Liraglutide leading to a decrease in the area under the curve (AUC) of Digoxin 16%, CMAX decreased by 31%. The average time for digoxin to reach the maximum concentration (TMAX) is slow from 1 hour to 1.5 hours. Based on these results, there is no need to adjust the dose of digoxin.

lisinopril

Using a single dose of Lisinopril 20mg with Liraglutide leads to a decrease in the AUC of Lisinopril 15g, CMAX decreased by 27%. The average time for Lisinopril to reach the maximum concentration (TMAX) slowed down from 6 hours to 8 hours when used with Liraglutide. Based on these results, there is no need to adjust the dose of Lisinopril.

Oral contraceptives

Liraglutide reduces the CMAX of Ethinyloestradiol and Levonorgestrel 12% and 13% respectively, after taking a single dose of oral contraceptives. TMAX is 1.5 hours slow when using Liraglutide with both compounds. There is no clinical effect on the overall absorption of Ethinylooestradiol or Levonorgestrel. Therefore, the contraceptive effect is expected not to be affected when used in combination with Liraglutide.

warfarin and other Coumarin derivatives

There are no studies on interaction. Clinical interactions are associated with poorly soluble active ingredients or narrow treatment index such as warfarin cannot be excluded, in patients using warfarin or other cooumarin derivatives started with Liraglutide treatment, recommendation to monitor international standard chemical ratio (INR) more often.

insulin

Do not observe the pharmacokinetic or pharmacokinetic interaction between Liraglutide and insulin detergir when using a single dose of insulin detix 0.5U/kg with 1.8mg Liraglutide in a stable state for patients with type 2 diabetes.

Storage

Store in the refrigerator (2 ° C - 8 ° C).

To be far from the cooling unit. Do not freeze.

After first use: Store below 30 ° C or in the refrigerator (2 ° C - 8 ° C).

Cover the pen to avoid light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.